For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

Novo Nordisk NVO has stumbled through 2025, with its shares down 41.5% year to date despite finally resolving U.S. supply constraints for its semaglutide-based GLP-1 blockbusters — Ozempic for type II ...

Attorney General Gentner Drummond announced a CVS Caremark settlement Dec. 8, 2025, but how they money will be paid has ...

On the heels of striking a deal with the Trump administration to reduce the prices of several of its most popular drugs for U.S. patients, Eli Lilly has unveiled additional savings for cash-paying ...

Eli Lilly and Co. this month rolled out plans to offer coverage of its popular obesity medications such as Zepbound through direct-to-employer arrangements set to begin in early 2026. The Indianapolis ...

Daniel Payne reports on how the health industry and Washington influence and impact each other. He joined STAT in 2025 after covering health care at POLITICO. You can reach Daniel on Signal at danielp ...

STOP TOUCHING YOUR FACE. MAJOR CHANGES COMING FOR THE WEIGHT LOSS DRUG COVERAGE IN THE NEW YEAR, AND THAT HAS PATIENTS SCRAMBLING. BUT THERE ARE SOME THINGS YOU CAN DO RIGHT NOW STARTING IN JANUARY, ...

The popularity of GLP-1 weight-loss medications continues to soar—and their uptake is helping to push down obesity rates on a national scale—but a safe, evidence-based way off the drugs isn’t yet in ...

Millions of people use injectable drugs like Wegovy to reach a healthier weight. But the weekly injections aren't for everybody — or every wallet. That's why experimental pills that could achieve ...

Birmingham, Alabama, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Curaechoice, the nation’s #1 leader in No-Cost Benefits Optimization Solutions, announced today that it has selected CVS Caremark at its pharmacy ...

Forbes contributors publish independent expert analyses and insights. Sally Pipes is a scholar and think tank CEO who writes on health care. "Competition is leading to lower prices, better value, and ...

Eli Lilly is upgraded to a "Strong Buy" due to 54% revenue growth, driven by Zepbound and Mounjaro's success in obesity and T2D. The company is expanding its pipeline with Orforglipron [oral GLP-1 ...